Molecular Characterization of PARP Inhibitor Response Reveals Co-Targeting Strategies in Advanced Prostate Cancer
Background/Objectives: Though PARP inhibition has improved the management of advanced prostate cancer, patient outcomes may be modest and disease progression on treatment is common. We sought to improve understanding of tumor cell response to PARP inhibition to support development of novel strategies to enhance and/or prolong PARP inhibitor (PARPi) efficacy. Methods: Cell viability assays and microscopy were used for initial characterization of PARPi response in models of advanced prostate cancer. RNA sequencing was performed to investigate time-dependent transcriptomic changes induced by PARP inhibition. Western blots, flow cytometry, and both additional viability assays and microscopy were used to validate RNA sequencing results and test potential
Authors
- Ryan R. Davis (ORCID: https://orcid.org/0000-0001-7439-6683)
- John D. McPherson (ORCID: https://orcid.org/0000-0001-8049-9347)
- Christopher A. Lucchesi (ORCID: https://orcid.org/0000-0001-8767-7003)
- Neelu Batra (ORCID: https://orcid.org/0000-0002-8924-2297)
- Hong Li (ORCID: https://orcid.org/0000-0001-5679-9980)
- Love A. Moore
- Akshaya Karthikeyan (ORCID: https://orcid.org/0009-0006-2939-8958)
- Bryan Correa Gonzalez
- Ethan Sandoval
- Marc Dall’Era
- Marion Hardy
- Anamitra Bhaumik
- Allen C. Gao
- Alan P. Lombard
Institutions
- VA Northern California Health Care System (US)
- University of California, Davis (US)
Publication Details
- Journal
- Cancers
- Published
- 2026-07-23
- DOI
- https://doi.org/10.3390/cancers18152381
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Cancer Institute